BioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, California
ANAHEIM, CA, April 10, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solution in the treatment of alcohol and opioid addition, today announced that the Company will have a tabletop exhibit at the American Society of Addiction Medicine (ASAM) 49th Annual Conference on April 12th through the 15th, in San Diego, California. ASAM is the leading addiction medicine professional society in the U.S. representing over 4,300 physicians, clinicians and professionals with a focus on addiction and its treatment.
The ASAM Addiction Medicine conference is widely recognized as the essential primer for physicians and other healthcare professionals who are preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients who medical problems are cause or exacerbated by substance use disorders.
Brady Granier, CEO, President, and Director, stated, “We are looking forward to attending ASAM’s 49th Annual Conference this week. Physicians, healthcare professionals and primary care providers are continuing to look for the latest and most innovated ways to help their patients that suffer from substance abuse. The BioCorRx® Recovery Program is an ideal match for primary care physicians who are entering the field of addiction medicine. This program enables these professionals to treat patients in their office with medicine like naltrexone, while providing outpatient behavioral therapy through our turnkey program. The event will also give us the opportunity to talk to many of the top addiction medicine providers about BICX102, our naltrexone implant for which we are seeking FDA approval.”
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 firstname.lastname@example.org
Released April 10, 2018